Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae

Oral Treatment Options for Ambulatory Patients with Urinary Tract Infections Caused by Extended-Spectrum- -Lactamase-Producing Escherichia coli

An increase in extended-spectrum-lactamase (ESBL)-producing Escherichia coli has been observed in outpatient settings. Consequently, 100 ESBL-positive E. coli isolates from ambulatory patients with clinically confirmed urinary tract infections were collected by a single laboratory between October 2004 and January 2008. Antimicrobial susceptibility testing was carried out using the oral antibiot...

Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.

An increase in extended-spectrum-beta-lactamase (ESBL)-producing Escherichia coli has been observed in outpatient settings. Consequently, 100 ESBL-positive E. coli isolates from ambulatory patients with clinically confirmed urinary tract infections were collected by a single laboratory between October 2004 and January 2008. Antimicrobial susceptibility testing was carried out using the oral ant...

Risk Factors for Community Acquired Extended-Spectrum Β-lactamase (ESBL) Producing Enterobacteriaceae Urinary Tract Infections (UTIs)

oral amoxicillin-clavulanic acid treatment in urinary tract infections caused by extended-spectrum beta-lactamase–producing organisms

results amc-susceptible esbl-producing escherichia coli, klebsiella pneumoniae and k. oxytoca were identified as the causative agents in 31, 14, and 1 patients, respectively. thirty-nine (84.7%) out of 46 patients were successfully treated with oral amc. additionally, 2 (4.3%) patients’ urine cultures turned to be negative, though their clinical complaints and leukocyturia had continued. in the...

Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae.

Ertapenem is active against extended-spectrum-β-lactamase (ESBL)-producing Enterobacteriaceae organisms but inactive against Pseudomonas aeruginosa and Acinetobacter baumannii. Due to a lack of therapeutic data for ertapenem in the treatment of ESBL bloodstream infections (BSIs), group 2 carbapenems (e.g., imipenem or meropenem) are often preferred for treatment of ESBL-producing Enterobacteria...